# Dominika Anna Nowis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8497221/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 102 papers | 7,766 citations | 126708 33 h-index | 54797 84 g-index |
| 106 all docs | 106 docs citations | 106 times ranked | 12180 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Ablation of Tmcc2 Gene Impairs Erythropoiesis in Mice. International Journal of Molecular Sciences, 2022, 23, 5263. | 1.8 | 3 |
| 2 | Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. OncoImmunology, 2021, 10, 1956143. | 2.1 | 30 |
| 3 | Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development. Cancers, 2021, 13, 870. | 1.7 | 28 |
| 4 | Inhibition of the ÊŸ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors. Cancer Letters, 2021, 507, 13-25. | 3.2 | 20 |
| 5 | The role of CD71+ erythroid cells in the regulation of the immune response. , 2021, 228, 107927. | | 37 |
| 6 | Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy. Human Molecular Genetics, 2021, 30, 226-233. | 1.4 | 8 |
| 7 | Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Research, 2021, 81, 6029-6043. | 0.4 | 20 |
| 8 | MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. Cell Death and Disease, 2021, 12, 1111. | 2.7 | 12 |
| 9 | Potent but transient immunosuppression of T-cells is a general feature of CD71+ erythroid cells. Communications Biology, 2021, 4, 1384. | 2.0 | 12 |
| 10 | Transport of nanoprobes in multicellular spheroids. Nanoscale, 2020, 12, 19880-19887. | 2.8 | 9 |
| 11 | Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. Cancers, 2020, 12, 2540. | 1.7 | 36 |
| 12 | Myeloid Cell-Derived Arginase in Cancer Immune Response. Frontiers in Immunology, 2020, 11, 938. | 2.2 | 249 |
| 13 | Immunoglobulin expression and the humoral immune response is regulated by the non-canonical poly(A) polymerase TENT5C. Nature Communications, 2020, 11, 2032. | 5.8 | 34 |
| 14 | The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA 5â€² cap modulates protein expression in living cells. Nucleic Acids Research, 2020, 48, 1607-1626. | 6.5 | 76 |
| 15 | Systematic Evaluation of Chemically Distinct Tissue Optical Clearing Techniques in Murine Lymph Nodes. Journal of Immunology, 2020, 204, 1395-1407. | 0.4 | 10 |
| 16 | Bone marrow is the preferred site of memory CD4+ T cell proliferation during recovery from sepsis. JCI Insight, 2020, 5, . | 2.3 | 16 |
| 17 | Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies. Blood, 2020, 136, 33-34. | 0.6 | 0 |
| 18 | Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. Nature Communications, 2019, 10, 3000. | 5.8 | 194 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. Oncogene, 2019, 38, 2860-2875. | 2.6 | 19 |
| 20 | Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer. Annals of Agricultural and Environmental Medicine, 2019, 26, 415-419. | 0.5 | 12 |
| 21 | Peroxiredoxin-5 is a negative survival predictor in ovarian cancer. Ginekologia Polska, 2019, 90, 1-6. | 0.3 | 7 |
| 22 | STING Signaling in Cancer Cells: Important or Not?. Archivum Immunologiae Et Therapiae Experimentalis, 2018, 66, 125-132. | 1.0 | 56 |
| 23 | Evidence of ER stress and UPR activation in patients with Brody disease and Brody syndrome. Neuropathology and Applied Neurobiology, 2018, 44, 533-536. | 1.8 | 1 |
| 24 | Neurodevelopmental phenotype caused by a de novo PTPN4 single nucleotide variant disrupting protein localization in neuronal dendritic spines. Clinical Genetics, 2018, 94, 581-585. | 1.0 | 13 |
| 25 | Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. Haematologica, 2018, 103, 1843-1852. | 1.7 | 8 |
| 26 | Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis. PLoS Medicine, 2018, 15, e1002505. | 3.9 | 31 |
| 27 | Bortezomib-Induced Muscle Toxicity in Multiple Myeloma. Journal of Neuropathology and Experimental Neurology, 2017, 76, 620-630. | 0.9 | 19 |
| 28 | Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles. Gene Therapy, 2017, 24, 113-119. | 2.3 | 3 |
| 29 | The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. Nature Communications, 2017, 8, 619. | 5.8 | 77 |
| 30 | Selection of an optimal promoter for gene transfer in normal B cells. Molecular Medicine Reports, 2017, 16, 3041-3048. | 1.1 | 6 |
| 31 | Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy. Annals of Oncology, 2017, 28, v418-v419. | 0.6 | 2 |
| 32 | Abstract 3975: Ovarian cancer cells release arginase-1-containing exosomes to suppress antitumor immune response. , 2017, , . | | 0 |
| 33 | MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. PLoS ONE, 2016, 11, e0155893. | 1.1 | 26 |
| 34 | Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. Oncotarget, 2016, 7, 1717-1731. | 0.8 | 48 |
| 35 | Abstract 4501: Immunophenotypic identities of clinical samples have the potential to correlate with overall survival in cytogenetically normal AML patients. , 2016, , . | | 0 |
| 36 | Abstract 5347: SK053, a small molecule inhibitor of enzymes involved in allosteric disulfide bonds formation, shows potent anti-leukemic effects and induces differentiation of human AML cells. , 2015, , . | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. Blood, 2015, 126, 4917-4917. | 0.6 | 0 |
| 38 | Statins impair glucose uptake in human cells. BMJ Open Diabetes Research and Care, 2014, 2, e000017. | 1.2 | 37 |
| 39 | Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model. Translational Oncology, 2014, 7, 570-579. | 1.7 | 17 |
| 40 | Peroxiredoxin-1 protects estrogen receptor Î± from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Research, 2014, 16, R79. | 2.2 | 52 |
| 41 | Adenanthin targets proteins involved in the regulation of disulphide bonds. Biochemical Pharmacology, 2014, 89, 210-216. | 2.0 | 36 |
| 42 | Peroxiredoxins-1 and 2 Affect Proliferation and Survival of Lymphoma Cells. Blood, 2014, 124, 1693-1693. | 0.6 | 1 |
| 43 | SK053, an Inhibitor of Enzymes Involved in Allosteric Disulfide Bonds Formation, Targets Expression of Histone Genes and Induces Differentiation of Human AML Cell. Blood, 2014, 124, 3503-3503. | 0.6 | 0 |
| 44 | GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. Cell Death and Disease, 2013, 4, e741-e741. | 2.7 | 52 |
| 45 | SK053 An Inhibitor Of Enzymes Involved In Allosteric Disulfide Bonds Formation Induces Differentiation Of Human AML Cells. Blood, 2013, 122, 4215-4215. | 0.6 | 0 |
| 46 | Statins Impair Glucose Uptake in Tumor Cells. Neoplasia, 2012, 14, 311-323. | 2.3 | 37 |
| 47 | Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity. Journal of Biological Chemistry, 2012, 287, 31983-31993. | 1.6 | 19 |
| 48 | Approaches to improve photodynamic therapy of cancer. Frontiers in Bioscience - Landmark, 2011, 16, 208. | 3.0 | 44 |
| 49 | Antitumor effects of the combination of cholesterol reducing drugs. Oncology Reports, 2011, 26, 169-76. | 1.2 | 7 |
| 50 | Optimization of activation requirements of immature mouse dendritic JAWSII cells for in vivo application. Oncology Reports, 2011, 25, 831-40. | 1.2 | 11 |
| 51 | Photodynamic therapy of cancer: An update. Ca-A Cancer Journal for Clinicians, 2011, 61, 250-281. | 157.7 | 3,902 |
| 52 | PDT-induced inflammatory and host responses. Photochemical and Photobiological Sciences, 2011, 10, 653-663. | 1.6 | 76 |
| 53 | Sorafenib Affects Membrane Complement Inhibitors and Improves Antitumor Activity of Rituximab,. Blood, 2011, 118, 3723-3723. | 0.6 | 0 |
| 54 | Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,. Blood, 2011, 118, 3722-3722. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels. Blood, 2011, 118, 1661-1661. | 0.6 | 0 |
| 56 | Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. Blood, 2010, 115, 3745-3755. | 0.6 | 40 |
| 57 | Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis: an International Journal on Programmed Cell Death, 2010, 15, 1050-1071. | 2.2 | 253 |
| 58 | Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1805, 53-71. | 3.3 | 292 |
| 59 | Proteolytic pathways involved in modulation of CD20 levels. Autophagy, 2010, 6, 810-812. | 4.3 | 4 |
| 60 | Studies of the Synthesis of All Stereoisomers of MG-132 Proteasome Inhibitors in the Tumor Targeting Approach. Journal of Medicinal Chemistry, 2010, 53, 1509-1518. | 2.9 | 38 |
| 61 | Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib. American Journal of Pathology, 2010, 176, 2658-2668. | 1.9 | 115 |
| 62 | Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. Cancer Letters, 2010, 288, 57-67. | 3.2 | 34 |
| 63 | Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response. Cancer Research, 2009, 69, 4235-4243. | 0.4 | 96 |
| 64 | Improvement of anti-tumor activity of photodynamic therapy through inhibition of cytoprotective mechanism in tumor cells. , 2009, , . | | 1 |
| 65 | The possible role of factor H in colon cancer resistance to complement attack. International Journal of Cancer, 2008, 122, 2030-2037. | 2.3 | 44 |
| 66 | Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. BMC Cancer, 2008, 8, 197. | 1.1 | 59 |
| 67 | Sarcolemmal Ca2+-ATPase ability to transport Ca2+ gradually diminishes after myocardial infarction in the rat. Cardiovascular Research, 2008, 81, 546-554. | 1.8 | 21 |
| 68 | Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20. PLoS Medicine, 2008, 5, e64. | 3.9 | 115 |
| 69 | Ciglitazone, an agonist of peroxisome proliferator-activated receptor Î³, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin. International Journal of Oncology, 2008, , . | 1.4 | 2 |
| 70 | Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin. International Journal of Oncology, 2008, 32, 249-55. | 1.4 | 3 |
| 71 | Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome. Acta Biochimica Polonica, 2008, 55, 75-84. | 0.3 | 3 |
| 72 | Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells. International Journal of Oncology, 2007, 31, 1547-52. | 1.4 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. International Journal of Oncology, 2007, , . | 1.4 | 6 |
| 74 | A novel function of VCP (valosin-containing protein; p97) in the control of N-glycosylation of proteins in the endoplasmic reticulum. Archives of Biochemistry and Biophysics, 2007, 462, 62-73. | 1.4 | 15 |
| 75 | TNF potentiates anticancer activity of bortezomib (VelcadeÂ®) through reduced expression of proteasome subunits and dysregulation of unfolded protein response. International Journal of Cancer, 2007, 121, 431-441. | 2.3 | 26 |
| 76 | Statins Impair Antitumor Effects of CD20 mAb by Inducing Conformational Changes of CD20.. Blood, 2007, 110, 2341-2341. | 0.6 | 0 |
| 77 | Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. International Journal of Oncology, 2007, 30, 1413-25. | 1.4 | 8 |
| 78 | Destabilization of the VCP-Ufd1-Npl4 complex is associated with decreased levels of ERAD substrates. Experimental Cell Research, 2006, 312, 2921-2932. | 1.2 | 36 |
| 79 | Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene, 2006, 25, 3365-3374. | 2.6 | 163 |
| 80 | Valosin-containing Protein (p97) Is a Regulator of Endoplasmic Reticulum Stress and of the Degradation of N-End Rule and Ubiquitin-Fusion Degradation Pathway Substrates in Mammalian Cells. Molecular Biology of the Cell, 2006, 17, 4606-4618. | 0.9 | 165 |
| 81 | The influence of photodynamic therapy on the immune response. Photodiagnosis and Photodynamic Therapy, 2005, 2, 283-298. | 1.3 | 83 |
| 82 | Direct tumor damage mechanisms of photodynamic therapy.. Acta Biochimica Polonica, 2005, 52, 339-352. | 0.3 | 222 |
| 83 | Direct tumor damage mechanisms of photodynamic therapy. Acta Biochimica Polonica, 2005, 52, 339-52. | 0.3 | 63 |
| 84 | CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice. Clinical Cancer Research, 2004, 10, 4165-4175. | 3.2 | 35 |
| 85 | Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. International Journal of Oncology, 2004, 24, 1149. | 1.4 | 17 |
| 86 | AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. Leukemia Research, 2004, 28, 53-61. | 0.4 | 4 |
| 87 | Effective Photoimmunotherapy of Murine Colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells. Clinical Cancer Research, 2004, 10, 4498-4508. | 3.2 | 142 |
| 88 | Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. International Journal of Oncology, 2004, 24, 1149-57. | 1.4 | 20 |
| 89 | Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncology Reports, 2004, 12, 1371-5. | 1.2 | 11 |
| 90 | Antitumor Effects of Photodynamic Therapy Are Potentiated by 2-Methoxyestradiol. Journal of Biological Chemistry, 2003, 278, 407-414. | 1.6 | 113 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clinical Cancer Research, 2003, 9, 5417-22. | 3.2 | 46 |
| 92 | Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. Oncology Reports, 2002, 9, 199. | 1.2 | 0 |
| 93 | Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. International Journal of Cancer, 2002, 97, 746-750. | 2.3 | 16 |
| 94 | Stimulation of TNF-Î± production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - a novel immunomodulator with potential application in tumour immunotherapy. Cancer Chemotherapy and Pharmacology, 2002, 50, 213-222. | 1.1 | 4 |
| 95 | Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. Oncology Reports, 2002, 9, 199-203. | 1.2 | 2 |
| 96 | Antitumor activity of tributyrin in murine melanoma model. Cancer Letters, 2001, 164, 143-148. | 3.2 | 16 |
| 97 | In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor. FEBS Letters, 2001, 503, 219-220. | 1.3 | 13 |
| 98 | Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line. Anticancer Research, 2001, 21, 4001-4. | 0.5 | 1 |
| 99 | Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. Oncology Reports, 0, , . | 1.2 | 1 |
| 100 | Rpt6. The AFCS-nature Molecule Pages, 0, , . | 0.2 | 0 |
| 101 | Rpt4. The AFCS-nature Molecule Pages, 0, , . | 0.2 | 0 |
| 102 | Rpt3. The AFCS-nature Molecule Pages, 0, , . | 0.2 | 0 |